Supernus Pharmaceuticals Total Depreciation and Amortization - Cash Flow 2011-2024 | SUPN
Supernus Pharmaceuticals total depreciation and amortization - cash flow from 2011 to 2024. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
Supernus Pharmaceuticals Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2024 |
$82 |
| 2023 |
$85 |
| 2022 |
$91 |
| 2021 |
$51 |
| 2020 |
$32 |
| 2019 |
$18 |
| 2018 |
$17 |
| 2017 |
$8 |
| 2016 |
$3 |
| 2015 |
$2 |
| 2014 |
$3 |
| 2013 |
$4 |
| 2012 |
$1 |
| 2011 |
$1 |
| 2010 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.872B |
$0.662B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
